In this episode we are joined by Alice Tew and Meera Desai. We discuss the history of the immunotherapy group, how and why it was established and how its work has evolved. We explore key projects including improving equity of access to second-line agents, the development of immunotherapy monographs, upcoming priorities for the group and much more.